Navigation Links
Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
Date:2/2/2009

LEUVEN, Belgium, Feb. 2 /PRNewswire-FirstCall/ -- A 74-year-old prostate cancer patient has become the first person in Belgium to be treated using a new, faster form of radiotherapy that extends more advanced care to more patients. The University Hospital of Leuven delivered the faster treatment using RapidArc radiotherapy technology from Varian Medical Systems (NYSE: VAR).

The patient, a retired military aircraft engineer from Kortenberg near Leuven, said he was pleased to be the country's first to receive this advanced form of image-guided intensity modulated radiotherapy (IMRT). By coincidence, his older brother was also treated for prostate cancer at the hospital two years ago, receiving a successful course of conventional IMRT.

"This patient is now feeling very well and he is very proud of being number one in Belgium," says Dr. Karin Haustermans, head of the Department of Oncology. "We are identifying patients for whom RapidArc is a beneficial treatment and we have been very pleased with the early results. Not everyone will be treated in this way but it appears to have major advantages in speed and precision for many of our prostate cancer patients."

Frank Van den Heuvel, director of physics, believes RapidArc will enable the hospital to bring down standard treatment slots from 12 minutes to ten minutes, enabling six patients to be treated per hour rather than five. "This is an entirely new technique for us so early treatments will inevitably take a little longer but once it becomes a part of our routine I believe we can achieve these targets," he said.

Prior to starting RapidArc treatments, research physicist Wouter Crijns carried out a series of tests revealing that RapidArc treatments could offer five significant benefits over and above conventional IMRT treatments. Along wi
'/>"/>

SOURCE Varian Medical Systems
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Aggressive Treatment Effective in Kids Brain Cancer
2. Physics, Math Provide Clues to Unraveling Cancer
3. Smithfield Foods Lean Generation(R) Deli Partnership with National Breast Cancer Foundation Celebrates $135,000 Contribution
4. Automated screening process may eventually reduce additional breast cancer surgeries
5. Variations in Gene DNA Boost Drinkers Cancer Risk
6. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
7. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
8. Skin color studies on tadpoles lead to cancer advance
9. Gene mutations increase risk for aggressive prostate cancer
10. Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer Detection
11. The Pancreatic Cancer Research and Education Act Addresses the Astounding Mortality of the Fourth Leading Cause of Cancer Death in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... Amanda Gardner HealthDay Reporter , , TUESDAY, ... frequently complain about having the procedure, which involves ... precancerous or cancerous growths. But a new ... to the less invasive and less time-consuming CT-based ... the standard of care for colon cancer screening. ...
(Date:5/23/2012)... 2012, SAN FRANCISCO Researchers in the United ... that also has anti-inflammatory properties, can be an ... obliterans syndrome (BOS), a life-threatening complication that occurs ... , BOS is the leading cause of ... occurs in part when the body repeatedly rejects ...
(Date:5/22/2012)... lip, cleft palate and other craniofacial disorders face ... face serious airway, feeding, speech and hearing problems, ... Swibel Rosenthal, MD, of Loyola University Medical Center ... of Otolaryngologic Clinics of North America . ... is complex," Rosenthal and colleagues write. "Otolaryngologic [ear-nose-throat] ...
(Date:5/22/2012)... (Phoenix, AZ May 22, 2012) -- Researchers at ... Medical Center have unveiled how and why the ... that could have real-world implications in military tactics, ... Barrow,s Laboratory of Visual Neuroscience, and Stephen Macknik, ... well known for their research into magic and ...
(Date:5/22/2012)... (May 22, 2012) Scientists at Virginia Commonwealth ... closer to developing a new therapy for acute ... agents obatoclax and sorafenib kill leukemia cells much ... are administered individually., Recently published in the journal ... Steven Grant, M.D., Shirley Carter Olsson and Sture ...
Breaking Medicine News(10 mins):Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Study shows antibiotic improves respiratory function in lung transplant patients 2Health News:Cleft lip/palate cause much more than cosmetic problems 2Health News:Barrow researchers use magic for discoveries 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3
... of having a pre-term baby may perhaps will like to ... pomegranate juice can prevent brain injury the fetus may be ... case of a pre-term delivery., ,Pomegranate juice contains polyphenols ... of neuroprotection and anti-aging effects. ,Researchers from Washington ...
... under a lot of cloud because of its alleged ... new study from the Women's Health Initiative (WHI) shows ... and postmenopausal women ,Hormone Replacement Therapy (HRT) ... like estrogen plus progestin, also known as synthetic progesterone. ...
... placebo controlled trial was done by Felicity cutts and ... Nine Valent Pneumococcal Conjugate Vaccine (9-PCV) against radiologically confirmed ... 12 months of age. ,The vaccine was found ... disease by 77%, all serotype invasive Pneumococcal disease by ...
... Cancer Society researchers conducted in interesting national survey that ... look at the prevailing myths about cancer in the minds ... 957 adults with no history of cancer to assess their ... identify any associated misconceptions. Participants were asked if five misconceptions ...
... Administration (FDA) has recently approved of a new prescription ... affects almost everybody. Gingivitis is an inflammation of the ... is believed that plaque-forming bacteria that live in the ... of gingivitis and substances released by the bacteria cause ...
... interesting national survey that was led by Ted Gansler, M.D., ... //in the minds of the public. They did a ... to assess their understanding of the disease and its ... if five misconceptions were true or false. And this is ...
Other Medicine News:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... and CHAPEL HILL, N.C., US, March 06, ... Orphan") and,Lantibio, Inc. ("Lantibio") today announced positive ... II clinical,study of Moli1901, an experimental compound ... developed by AOP Orphan in,Europe under a ...
... Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters at,the ... Asthma, and,Immunology from February 23 - 27, 2007 ... a survey of 202 otolaryngologists,(ENTs) and allergists in ... of chronic sinusitis (CS), the knowledge and attitudes ...
Other Medicine Technology:AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5
Designed to provide more effective infusion, .90mm(20 G) ultra thinwall cannula with 45 beveled tip allows 30 percent more fluid flow than a regular wall cannula...
...
...
...
Medicine Products: